Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Inclusion Criteria

• •Age 18 to 75 years
• •Diagnosis of HL or NHL eligible for autologous transplantation
• •30 days since last cycle of chemotherapy
• •ECOG performance status of 0 or 1
• •The patient has recovered from all acute toxic effects of prior chemotherapy
• •WBC \>3.0 X 109/l
• •Absolute PMN count \>1.5 X 109/l
• •PLT count \>100 X 109/l
• •Serum creatinine ≤ 2.2 mg/dl
• •AST (SGOT), ALT (SGPT) and total bilirubin \< 2X upper limit of normal (ULN)
• •Left ventricle ejection fraction \> 45% (by ECHO or MUGA scan)
• •FEV1 \> 60% of predicted or DLCO \> 45% of predicted
• •Negative for HIV on standard transplant workup
• •Signed informed consent
• •Are surgically or biologically sterile or willing to practice acceptable birth control, as follows:
• •* Females of child bearing potential must agree to abstain from sexual activity or to use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period. Women of child bearing potential must have a negative serum or urine pregnancy test at the time of enrollment. Acceptable methods of birth control include oral contraceptive, intrauterine device (IUD), transdermal/implanted or injected contraceptives and abstinence.
• •* Males must agree to abstain from sexual activity or agree to utilize a medically approved contraception method during and for 3 months after the treatment period